The combination petosemtamab + pembro showcased early clinical efficacy with a tolerable toxicity profile when used in the first-line setting for pts w/ recurrent or metastatic HNSCC. #hncsm #oncology onclive.com/view/frontline…

Nivolumab + ipilimumab & chemo sustained an OS benefit compared w/ chemo alone in pts w/ metastatic NSCLC, irrespective of PD-L1 expression or histology, according to 5-year data from the phase 3 CheckMate 9LA trial. #ASCO24 #lcsm #oncology onclive.com/view/nivolumab…

Uproleselan combined with chemotherapy showed a significant OS improvement in primary refractory AML patients. Dana-Farber #leusm #ASCO24 onclive.com/view/os-data-c…

In this #OncLive series, 'Genomic Testing for Improved Treatments in Breast Cancer', Drs Cobain and O’Shaughnessy provide insights into the evolving therapeutic landscape for early-stage #BreastCancer . Joyce O'Shaughnessy, MD #oncology Watch more here: onclive.com/view/evolving-…

RAI-R DTC is a type of #thyroidcancer that is historically difficult to treat. In this article sponsored by Eisai US, Dr. Francis Worden discusses a treatment option for RAI-R DTC and the importance of real-world data bit.ly/3KIwc7P

BREAKING: U.S. FDA Approves Blinatumomab for CD19+ B-ALL in the Consolidation Phase onclive.com/view/fda-appro…

Hello, This is Philip McCarthy from Roswell Park reporting for OncLive.com from @EHA in #Madrid . The meeting started yesterday with multiple Pharma-sponsored sessions. A lot of great sessions today and a large number of posters to view. More to discuss tomorrow.

BREAKINGThe U.S. FDA had approved durvalumab in combination with carboplatin plus paclitaxel, followed by single-agent durvalumab, for adult patients with primary advanced or recurrent #EndometrialCancer that is mismatch repair deficient. #Oncology onclive.com/view/fda-appro…

Liso-Cel Associated With Improved Benefit in Earlier Lines of Therapy in R/R Mantle Cell Lymphoma European Hematology Association #EHA2024 #lymsm onclive.com/view/liso-cel-…

Anemia Does Not Diminish Benefit With Ruxolitinib Treatment in Myelofibrosis European Hematology Association #EHA2024 #mpnsm #oncology onclive.com/view/anemia-do…

CAR T-Cell Therapy Is Safe, Feasible in Outpatient Setting for NHL European Hematology Association #EHA2024 #leusm onclive.com/view/car-t-cel…

Englumafusp alfa/Glofitamab Combo Shows Early Responses in R/R Aggressive non-Hodgkin Lymphoma Université de Lille European Hematology Association #EHA2024 onclive.com/view/englumafu…

Frontline Blinatumomab Demonstrates “Impressive” Activity in Down Syndrome B-ALL #leusm #oncology #EHA2024

onclive.com/view/frontline…

CD7-Directed CAR T-Cell Therapy WU-CART-007 Is Safe in R/R T-ALL/LBL European Hematology Association
#EHA2024 #leusm #lymsm #oncology onclive.com/view/cd7-direc…

Disease Duration, Elevated WBC Count, and VAF Predict Disease Progression in Polycythemia Vera Levine Cancer European Hematology Association #EHA2024
onclive.com/view/disease-d…

HOVON-146 Study Shows Blinatumomab Boosts B-ALL Outcomes #leusm #oncology #EHA2024 European Hematology Association

onclive.com/view/hovon-146…

Observational Study Finds Progression Common in Lower-Risk Myelofibrosis Levine Cancer European Hematology Association #EHA2024 onclive.com/view/observati…

Zanubrutinib Plus Venetoclax Generates 100% ORR in Treatment-Naive Del17p/TP53+ CLL/SLL Ospedale San Raffaele European Hematology Association #EHA2024 #lymsm #leusm
onclive.com/view/zanubruti…

Dr Consuelo Bertossi of Uniklinik Ulm also stopped by today to share some expert insights on the landscape of TP53 mutations and their prognostic value for patients with CLL. Keep following along for updates like this and more! @EHA #EHA24 #lymsm